March 18, 2022
1 min watch
Save
VIDEO: Single agent pembrolizumab agnostic to tumor histology
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Kevin Kalinsky, MD, discussed the approval of single agent pembrolizumab, which he said is agnostic to tumor histology, as well as the role of poly(ADP-ribose) polymerase (PARP) inhibitors for patients with BRCA mutations.
Kalinsky, an associate professor of medicine at New York-Presbyterian Hospital/Columbia University Medical Center, said in reference to presentations at 39th Miami Breast Conference, "If patients happen to have high tumor mutational burden or are MSI-high, there is an approval for single agent pembrolizumab that is agnostic to tumor histology."
Published by:
Sources/Disclosures
Collapse
Disclosures:
Kalinsky reports no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.